Scientists model 900 cell receptors, drug targetsFebruary 17, 2006In an important step toward accelerating drug discovery, researchers have created computer models of more than 900 cell receptors from a class of proteins known to be important drug targets. The models, which are now freely available to noncommercial users, promise to help scientists narrow their research inquiries, potentially speeding up the discovery of new drug compounds. The research appears in the February 17, 2006 issue of the Public Library of Science Computational Biology. "This is the first time anyone has modeled them all with an algorithm that improves the accuracy of the structure," said Jeffrey Skolnick Georgia Research Alliance Eminent Scholar in Computational Systems Biology at the Georgia Institute of Technology. "I think it's going to have significant impact, because it's a major class of drug design." One of the hottest areas in drug research, rational drug design uses three-dimensional computer simulations to study how different drugs and their cellular targets interact with each other. This technique can help research teams discover which compounds are most likely to achieve the desired results, potentially accelerating the speed of drug research and allowing for the discovery of reactions that may not have been found through traditional means. G protein-coupled receptors are targeted by an estimated one-third of all drugs and convey chemical signals from the outside of cells to the inside. But because they tend to fall apart once they're removed from the outer membrane of the cell, scientists have only been able to solve the three-dimensional structure for a few of them. And those aren't even good drug targets. Until now, researchers wanting to model any of the others have had to base their models on the structures of the existing, non-pharmacological receptors. Since those receptors, according to Skolnick, are evolutionarily distant from the proteins thought to be good drug targets, the models aren't very accurate. Using an algorithm they developed known as TASSER, a team of researchers led by Skolnick, then at the University of Buffalo, created three-dimensional structures of all the GPCRs below 500 amino acids in the human genome. "The solved GPCRs are of the same approximate shape as the ones known to be good drug targets, only they differ in details. But it's the details, the packing of the helixes, their angles, their size, that differentiate the drug binding sites of GPCRs from one another," said Skolnick, "TASSER appears to have the capacity to give us a reasonable picture of the structure of these proteins." Of the 907 models TASSER has helped create, Skolnick estimates that about 820 are accurate enough to be useful to researchers. "There's still room for significant improvement. They're like cartoons - they kind of look like reality sometimes, but they can be used to help design experiments," said Skolnick. The mission of the Center for the Study of Systems Biology at Georgia Tech, of which Skolnick is the director, is to essentially simulate life on a computer by building accurate three-dimensional models of the components of life, such as individual proteins and collections of proteins. "The idea is to simulate these proteins, introduce a drug structure and see how they interact," said Skolnick. The next step for Skolnick is solving the structure of proteins that have been implicated as a factor in various types of cancer. Georgia Institute of Technology |
|||||||||||||||||||||
| Related Drug Targets Current Events and Drug Targets News Articles WPI Researchers Take Aim at Hard-to-Treat Fungal Infections A team of researchers at the Worcester Polytechnic Institute (WPI) Life Sciences and Bioengineering Center at Gateway Park has developed a new model system to study fungal infections. Why can't chimps speak? If humans are genetically related to chimps, why did our brains develop the innate ability for language and speech while theirs did not? Researchers 'notch' a victory toward new kind of cancer drug Scientists have devised an innovative way to disarm a key protein considered to be "undruggable," meaning that all previous efforts to develop a drug against it have failed. Study points to new uses, unexpected side effects of already-existing drugs Scientists at the University of North Carolina at Chapel Hill School of Medicine and the University of California, San Francisco have developed and experimentally tested a technique to predict new target diseases for existing drugs. This is your brain on fatty acids Saturated fats have a deservedly bad reputation, but Johns Hopkins scientists have discovered that a sticky lipid occurring naturally at high levels in the brain may help us memorize grandma's recipe for cinnamon buns, as well as recall how, decades ago, she served them up steaming from the oven. Researchers use drug-radiation combo to eradicate lung cancer Researchers at UT Southwestern Medical Center have eliminated non-small cell lung (NSCL) cancer in mice by using an investigative drug called BEZ235 in combination with low-dose radiation. Protein interaction network can respond Helicobacter pylori infection? Helicobacter pylori (H pylori) is a gram negative bacterium which infects about 50% of the world population. H pylori colonization causes a strong systemic immune response. Viagra relatives may shrink abnormally large hearts Compounds related to Viagra, which is already in clinical trials to prevent heart failure, may also counter the disease in a different way, according to a study published online today in the journal Circulation Research. Drug discovery process more accurate, less expensive using novel mass spectrometry application Cancer and cell biology experts at the University of Cincinnati (UC) have developed a new mass spectrometry-based tool they say provides more precise, cost-effective data collection for drug discovery efforts. UT scientists discover link between protein and lung disease In a development that could lead to a novel approach to the treatment of a devastating lung disease, biochemists at The University of Texas Health Science Center at Houston report they are the first to link the osteopontin (OPN) protein to chronic obstructive pulmonary disease (COPD). More Drug Targets Current Events and Drug Targets News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||